Global Information
회사소개 | 문의 | 위시리스트

세계의 GABA 수용체 작용제 시장 : 투약량, 가격, 임상 파이프라인 전망

Global GABA Receptor Agonist Drug Market, Dosage, Price & Clinical Pipeline Outlook 2024

리서치사 KuicK Research
발행일 2018년 03월 상품 코드 616600
페이지 정보 영문 220 Pages
가격
US $ 2,200 ₩ 2,588,000 Unprintable PDF by E-mail (Single User License)
US $ 3,300 ₩ 3,883,000 CD-ROM
US $ 4,000 ₩ 4,707,000 Hard Copy
US $ 4,400 ₩ 5,177,000 Printable PDF by E-mail (Multi-User License)

주의 : 본 보고서는 DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로, 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



세계의 GABA 수용체 작용제 시장 : 투약량, 가격, 임상 파이프라인 전망 Global GABA Receptor Agonist Drug Market, Dosage, Price & Clinical Pipeline Outlook 2024
발행일 : 2018년 03월 페이지 정보 : 영문 220 Pages

세계의 GABA(감마 아미노낙산) 수용체 작용제 시장을 분석했으며, 제품 개요와 동작 메커니즘, 투약량·가격별 시장 분석, 임상시험 파이프라인 상황 개요 및 주요 기업 개요 등의 정보를 정리하여 전해드립니다.

제1장 GABA(감마 아미노낙산) : 서론

  • GABA(감마 아미노낙산) : 중추신경계의 주요 억제성 신경전달물질
  • GABA 수용체와 중요성
  • GABA 수용체 : 역할과 동작 메커니즘

제2장 GABA 수용체 치료제의 주요 클래스

  • GABA 수용체 작용제(활성제)
  • GABA 수용체 작용제(억제제)

제3장 GABA 수용체 시장 세분화 : 종류별

  • GABAA
  • GABAB

제4장 GABA 수용체 치료제 시장 분석 : 투약량·가격별

  • 가바펜틴(Gralise, Neurontin, Gabarone, Fanatrex)
  • 졸피뎀
  • 기타 출시약

제5장 유망 GABA 수용체 작용제 치료제

  • Bamaluzole
  • Phenibut
  • Baclofen
  • Gaboxadol
  • Klonopin(clonazepam)
  • Tiagbine
  • 영양보조식품으로서의 GABA

제6장 세계 - GABA 수용체 작용제의 동향·시장 역학

  • GABA 시장 부문으로의 유망 치료제 참여
  • 정신적 질환 시장의 기회 증대

제7장 GABA 수용체 작용제 시장 분석 : 적응증별

  • 주의력결핍 과잉행동장애(ADHD)
  • 정신질환 & 우울증
  • 알츠하이머
  • 간질 & 발작
  • 불안신경증 & 수면장애
  • 비만 & 알코올 중독

제8장 GABA 수용체 작용제 시장 분석 : 지역별

  • 미국
  • 유럽
  • 아시아태평양
  • 기타

제9장 GABA 수용체 작용제 시장 촉진요인

  • GABA 관련 질환 이환율의 상승
  • 연구개발의 증가
  • 안정된 임상 파이프라인의 존재

제10장 GABA 수용체 작용제 시장이 해결해야 할 과제

  • 과학적 & 기술적 제한
  • GABA 치료제 부문에서 연구의 제한 & 비용 요인
  • GABA 수용체 작용제의 인식 부족 & 낮은 시장 침투율
  • 규제되지 않은 시장 & 엄격한 FDA 규제

제11장 세계의 GABA 수용체 작용제 시장 예측

제12장 세계의 GABA 수용체 작용제 임상 파이프라인 : 기업·적응증·위상별

  • 파이프라인 개요
  • 미확인
  • 연구
  • 전임상
  • 임상
  • 제I상
  • 제II상
  • 제III상
  • 등록전

제13장 세계의 GABA 수용체 작용제 임상 인사이트 : 기업·적응증별

제14장 경쟁 분석

  • Advicenne
  • AstraZeneca
  • Athena Drug Delivery Solutions
  • Biocodex
  • Elan Corporation
  • Eli Lilly & Company
  • H.LundBeck
  • GlaxoSmithKline
  • NovaDel Pharma
  • Novartis
  • OVATION Pharmaceuticals
  • Osmotica Pharmaceutical
  • Pfizer
  • sanofi-aventis
  • VIVUS
  • XenoPort
KSA 18.03.29

Report Highlights:

  • Global GABA Drugs Market Analysis by Dosage & Price
  • Promising GABA Receptor Agonist Therapeutics
  • Trends and Market Dynamics of GABA Receptor Agonist
  • Global GABA Receptor Agonists Clinical Pipeline = 49 Drugs
  • Marketed Global GABA Receptor Agonists Clinical Insight = 28 Drugs
  • GABA Receptor Agonist Market Analysis by Indication

Brain is indeed the vital organ of the body designated as the coordinating center of sensations, intellectual and nervous activities through various chemicals and receptors. Thus any dysregulation in the levels of chemicals or receptors can result in development of Central Nervous System Disorders. One of such component is Gamma-Aminobutyric Acid (GABA) which is an inhibitory neurotransmitter present in brain has been found to be dominantly involved in developing central nervous system disorders.

Dysregulation of GABA can result in neurodegenerative disorders like Alzheimer's disease and Parkinson's Disease; Psychiatric Disorders like Epilepsy, Depression, Anxiety, Sleep Disorders, ADHD, Alcoholism etc. All these diseases have been found to be developed by inappropriate levels and functioning of GABA. Lack of studies related to these conditions has resulted in highly unmet medical needs of this group of population.

Recent innovations in science and technology have aided better management of complicated diseases with better understanding of affected target of the brain and thus developing highly effective therapies which specifically treat the neurological and psychological diseases from their root cause rather than decreasing the symptoms of the disease. Increasing demand of therapies for these conditions and research findings about GABA has led to the development of a new class of therapeutics called GABA receptors which have been found to be highly effective for a wide range of neurological and psychological disorders.

Continuous increase in all of the above mentioned indications also leads to a significant decrease in the productivity affecting the global economy. This scenario alarmed the academia, healthcare and pharmaceutical industry to shift their focus towards this group of disorders. Cumulative efforts of these industries have led to the development and commercialization of more than 20 therapeutics in the market; collecting high revenues owing to increasing awareness and concern regarding neurological disorders.

Increasing ageing population and growing incidences of neurodegenerative disorders like Alzheimer's disease and Parkinson's disease in older population will drive the market for GABA receptors in the coming future. Moreover, increase in prevalence of risk factors (such as diabetes), and lifestyle changes (such as alcohol consumption) also increase the chances of developing a mental disorder in adult and older group of population. Moreover psychological disorders like ADHD, anxiety and depression are occurring at an increasing rate in younger population which will again drive the global market for GABA receptors due to increasing needs to manage these disorders. Additionally, lack of effective treatment options in the market indicates a progressive growth and consumer acceptance for global GABA receptor Market.

However, low awareness regarding treatment of mental disorders, in developing nations like India; Russia; Brazil etc. is still a major challenge for the market growth. However, increased surveys, studies and awareness programs will surely aid in coping up with current challenges of GABA receptor market growth in these regions. Therefore, developing regions show highly opportunistic market for GABA receptors due to high prevalence of the disorders in these regions.

Increased funding by government and private organizations across emerging economies for treatment of neurological disorders is expected to provide growth opportunities for the market growth. Global GABA receptor market is growing at an impressive 6 CAGR with growing sales of major drugs in the market such as Baclofen and Propofol. Sales of Propofol is expected to reach US$ 6 Billion and Baclofen will collected more than US$ 400 Million for the developer pharmaceutical company in 2024. Additionally, exponential increase in the incidences of neurodegenerative, psychiatric and psychological disorders is going to fuel Global GABA receptor market in the coming future.

We have analyzed the Global Market for GABA receptors by studying the target patient base in major regions of the world, increasing awareness about the indications and current and future sales of various GABA receptors. Additionally, the report includes price and dosage analysis, treatment costs of the GABA receptors market products. Our research suggests that GABA Receptors have a highly progressive market with several promising products in the pipeline and increasing acceptance by consumers and end users.

Table of Contents

1. Prologue to (Gamma Amino Butyric Acid) GABA

  • 1.1 Gamma - Amino Butyric Acid (GABA) - Chief Inhibitory Neurotransmitter of the Central Nervous System
  • 1.2 GABA Receptors & Their Importance
  • 1.3 GABA Receptor - Role & it's Working Mechanism

2. Major Classes of GABA Receptor Therapeutics

  • 2.1 GABA Receptor Agonist (Activators)
  • 2.2 GABA Receptor Antagonist (Inhibitors)

3. GABA Receptor Market Segmentation by Type

  • 3.1 GABAA
  • 3.2 GABAB

4. Global GABA Drugs Market Analysis by Dosage & Price

  • 4.1 Gabapentin (Gralise, Neurontin, Gabarone, Fanatrex)
    • 4.1.1 Horizant (Gabapentin Enacarbil)
    • 4.1.2 Regnite (Gabapentin Enacarbil,Japan)
    • 4.1.3 Solzira (Gabapentin Enacbril)
    • 4.1.4 Gralise (Gabapentin Enacbril)
  • 4.2 Zolpidem
    • 4.2.1 Ambien & Ambien CR ( Zolpidem Tartrate)
    • 4.2.2 Edluar
    • 4.2.3 Intermezzo
    • 4.2.1 Zolpimist
  • 4.3 Other Marketed GABA Receptor Therapeutics - Dosage & Price Analysis
    • 4.3.1 Diastat AcuDial (Diazepam)
    • 4.3.2 Campral EC (Acamprosate)
    • 4.3.3 Stiripentol (Diacomit)
    • 4.3.4 Gamibetal (GABOB)
    • 4.3.5 Loreclezole
    • 4.3.6 Lunesta(Eszopiclone)
    • 4.3.7 Piacmilon
    • 4.3.8 Onfi(Clobazam)
    • 4.3.9 Gabrene (Progabide)
    • 4.3.10 Diprivan (Propofol)
    • 4.3.11 Regtect
    • 4.3.12 Sonata Oral (Zaleplon, Starnoc, Andate)
    • 4.3.13 Topamax Migraine

5. Promising GABA Receptor Agonist Therapeutics

  • 5.1 Bamaluzole
  • 5.2 Phenibut
  • 5.3 Baclofen
  • 5.4 Gaboxadol
  • 5.5 Klonopin (clonazepam)
  • 5.6 Tiagbine
  • 5.7 GABA as Food Supplement

6. Global - Trends and Market Dynamics of GABA Receptor Agonist

  • 6.1 Entry of Promising Therapeutics into the GABA Market Segment
  • 6.2 Increasing Opportunities in Psychological Disorders Market

7. GABA Receptor Agonist Market Analysis by Indication

  • 7.1 Attention Deficit Hyperactivity Disorder (ADHD)
  • 7.2 Psychiatric Disorders & Depression
  • 7.3 Alzheimer
  • 7.4 Epilepsy & Seizure
  • 7.5 Anxiety & Sleep Disorders
  • 7.6 Obesity & Alcoholism

8. GABA Receptor Market Analysis by Region

  • 8.1 US
  • 8.2 Europe
  • 8.3 Asia Pacific
  • 8.4 Rest of the World

9. GABA Receptor Agonist Market Driving Parameters

  • 9.1 Increasing Prevalence of GABA Related Disorders
  • 9.2 Increase in Research & Development
  • 9.3 Presence of Robust Clinical Pipeline

10. GABA Receptor Agonist Market Challenges

  • 10.1 Scientific & Technical Limitations
  • 10.2 Limited Research in GABA Therapeutics Segment & Cost Factor
  • 10.3 Lack of Awareness & Low Market Penetration of GABA Receptor Agonist
  • 10.4 Unregulated Market & Stringent FDA Regulations

11. Global GABA Receptor Agonist Market Future Forecast

12. Global GABA Receptor Agonists Clinical Pipeline by Company, Indication & Phase

  • 12.1 Global GABA Receptor Agonists Pipeline Overview
  • 12.2 Unknown
  • 12.3 Research
  • 12.4 Preclinical
  • 12.5 Clinical
  • 12.6 Phase-I
  • 12.7 Phase-II
  • 12.8 Phase-III
  • 12.9 Preregistration

13. Marketed GABA Receptor Agonists Clinical Insight by Company & Indication

14. Competitive Analysis

  • 14.1 Advicenne
  • 14.2 AstraZeneca
  • 14.3 Athena Drug Delivery Solutions
  • 14.4 Biocodex
  • 14.5 Elan Corporation
  • 14.6 Eli Lilly & Company
  • 14.7 H.LundBeck
  • 14.8 GlaxoSmithKline
  • 14.9 NovaDel Pharma
  • 14.10 Novartis
  • 14.11 OVATION Pharmaceuticals
  • 14.12 Osmotica Pharmaceutical
  • 14.13 Pfizer
  • 14.14 sanofi-aventis
  • 14.15 VIVUS
  • 14.16 XenoPort

List of Figures

  • Figure 1-1: GABA - Most Abundant Neurotransmitter
  • Figure 1-2: Features of GABA Receptors
  • Figure 1-3: GABA Receptor Activation & Function
  • Figure 2-1: Potential Therapeutic Role of GABA
  • Figure 3-1: Structure of GABAA
  • Figure 4-1: Gabapentin (Neurontin) - Dosage Analysis (mg)
  • Figure 4-2: Gabapentin (Neurontin) - Price Analysis (US$), 2018
  • Figure 4-3: Horizant - Dosage Analysis by Indication (mg/day)
  • Figure 4-4: Horizant- Price Analysis for 300mg & 600mg Pack(US$), 2018
  • Figure 4-5: Regnite - Price Analysis by Region (US$), 2018
  • Figure 4-6: Ambien - Maximum Permissible Dosage by Gender (mg)
  • Figure 4-7: Price Analysis -Ambien CR Oral Tablet (US$/30 Tablet Pack), 2018
  • Figure 4-8: Intermezzo - Dosage Analysis (mg)
  • Figure 4-9: Zolpidem - Price Analysis by Product, 2018
  • Figure 4-10: Diazepam Rectal Gel - Dosage Analysis by Age (mg/kg)
  • Figure 4-11: Diazepalm - Price Analysis by Product, 2018
  • Figure 4-12: Dosage Analysis - Acamprosate Tablets per day by Weight
  • Figure 4-13: GABOB- Maximum Recommended Dosage in Children by Condition (mg/Day)
  • Figure 4-14: GABOB - Maximum Recommended Dosage in Adults by Condition (mg/Day)
  • Figure 4-15: Propofol- Price Analysis (US$/ml), 2018
  • Figure 4-16: Global - Propofol Sales Analysis (US$ Million), 2013
  • Figure 4-17: Sonata Oral - Price Analysis (US$), 2018
  • Figure 4-18: Topomax - Monotherapy Dosage Analysis for patients >10 years (mg)
  • Figure 4-19: Topamax - Monotherapy Dosage (mg) Analysis for Patients < 10 years by Weight (kg)
  • Figure 4-20: Topamax - Price Analysis for 15 Tablet pack (mg), 2018
  • Figure 5-1: Global - Propofol Sales Forecast (US$ Billion), 2015-2024
  • Figure 5-2: Baclofen - Price Analysis (US$/mg), 2018
  • Figure 5-3: Baclofen - Intrathecal Solution Price Analysis (US$/ml), 2018
  • Figure 5-4: Global - Baclofen Sales Estimates (US$ Million), 2015 -2024
  • Figure 5-5: Tiagbine - Dosage Analysis by Indication (mg)
  • Figure 7-1: GABA Market Segmentation by Indication
  • Figure 7-2: Global - ADHD Prevalence by Region (%), 2016
  • Figure 7-3: Global - Prevalence of GABA Related Disorders (%), 2017
  • Figure 7-4: Global - Alzheimer Prevalence Forecast (Million) 2016-2050
  • Figure 7-5: Global- Number of Patients Diagnosed by Epilepsy (Million), 2016
  • Figure 7-6: Sleep Disorders Prevalence by Region (%), 2016
  • Figure 7-7: Global - Estimated Annual Cost of Sleep Disorder (US$ Million), 2016
  • Figure 8-1: US- ADHD Prevalence by Age (%), 2018
  • Figure 8-2: US-ADHD Prevalence by Gender (%), 2018
  • Figure 8-3: US- ADHD Prevalence by Race (%), 2018
  • Figure 8-4: US -People Diagnosed with GABA Related Disorders (Million), 2012-2016
  • Figure 8-5: Europe - Alzheimer's Prevalence by Age (%), 2014-2016
  • Figure 8-6: Asia - Prevalence of ADHD among Children by Region (%), 2012-2016
  • Figure 8-7: Asia Pacific - GABA Related Sleep Disorder Prevalence (%), 2015-2016
  • Figure 9-1: Driving Factors of GABA Agonist Market
  • Figure 9-2: Current Psychiatric Drug Pipeline, 2018
  • Figure 10-1: GABA Receptor Agonist Market Challenges
  • Figure 12-1: Global - GABA Receptor Agonists Clinical Pipeline (%), 2018 till 2024
  • Figure 12-2: Global - GABA Receptor Agonists Clinical Pipeline (Number), 2018 till 2024
  • Figure 12-3: Global - GABA Receptor Agonists Clinical Pipeline (%),2018 till 2024
  • Figure 12-4: Global - GABA Receptor Agonists Clinical Pipeline (Number), 2018 till 2024
Back to Top
전화 문의
F A Q